Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results. As of 2024, it is under development for the management of erythropoietic protoporphyria (EPP).
{{Drugbox | IUPAC_name = {4-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}{5-(methylsulfonyl)-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl}methanone | image = Bitopertin.svg | image_class = skin-invert-image | width = 270
| IUPHAR_ligand = 7546 | CAS_number = 845614-11-1 | ChemSpiderID = 25034798 | PubChem = 24946690 | ATC_prefix = none | ChEMBL = 1169880 | UNII = Q8L6AN59YY | KEGG = D10186
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).